MedTrace Logo

Local Treatment With RP for Newly-diagnosed mPCa

NCT02138721 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-12-20

No results posted yet for this study

Summary

The objective of this study is to evaluate the role of local treatment with radical prostatectomy in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer.

Conditions

  • Prostatic Neoplasms
  • Neoplasm Metastasis

Interventions

PROCEDURE

Radical Prostatectomy (RP)

Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Nicolaas Lumen, MD, PhD · University Hospital, Ghent

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02138721 on ClinicalTrials.gov